Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: Preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells

Journal of Microencapsulation

Volumn 29, Issue 7, 2012, Pages 685-694

  Gaca, Sebastian ^a   Reichert, Sebastian ^a   Rödel, Claus ^a   Rödel, Franz ^a   Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Ionising radiation; MiRNA; Nanoparticles; Survivin

Indexed keywords

HUMAN SERUM ALBUMIN; NANOCARRIER; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; SURVIVIN;

ARTICLE; CARCINOMA CELL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RELEASE; GENE SILENCING; HUMAN; HUMAN CELL; IONIZING RADIATION; PARTICLE SIZE; PLASMID; PROTEIN EXPRESSION; RADIOSENSITIZATION; RNA INTERFERENCE; TUMOR CELL LINE;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICRORNAS; NANOPARTICLES; PARTICLE SIZE; RADIATION-SENSITIZING AGENTS; SERUM ALBUMIN;

EID: 84868686600     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.680511     Document Type: Article

References (30)

1. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer, 2008;8(1):61-70.
2. Arnedo A, Irache JM, Merodio M, Espuelas Millán MS. Albumin NP improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Controlled Release, 2004;94(1):217-27. (Pubitemid 37542391)
3. Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res, 2000;91(11):1204-9.
4. Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic NP for controlled delivery of plasmid DNA. Int J Pharm, 2007;343(1-2):247-54. (Pubitemid 47334869)
5. Boulaiz H, Marchal JA, Prados J, Melguizo C, Aránega A. Non-viral and viral vectors for gene therapy. Cell Mol Biol (Noisy-le-grand), 2005;51(1):3-22. (Pubitemid 43093388)
6. Capalbo G, Rodel C, Stauber RH, Knauer SK, Bache M, Kappler M, Rödel F. The role of survivin for radiation therapy: Prognostic and predictive factor and therapeutic target. Strahlenther Onkol, 2007;183(11):593-99. (Pubitemid 350124276)
7. Gardlik R, Palffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit, 2005;11(4):RA110-121. (Pubitemid 40546958)
8. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Controlled Release, 1999;60(2-3):149-60. (Pubitemid 29335941)
9. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol, 2010;624:25-37.
10. Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Delivery Rev, 2006;58(14):1523-31. (Pubitemid 44820504)
11. Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and NP. J Controlled Release, 2008;132(3):171-83.
12. Kreuter J. NP-A historical perspective. Int J Pharm, 2007;331(1):1-10.
13. Kufleitner J, Wagner S, Worek F, von Briesen H, Kreuter J. Adsorption of obidoxime onto human serum albumin NP: Drug loading, particle size and drug release. J Microencapsulation, 2010;27(6):506-13.
14. Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. Human serum albumin (HSA) NP: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm, 2008;347(1-2):109- 17. (Pubitemid 350180317)
15. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) NP. Int J Pharm, 2003;257(1-2):169-80. (Pubitemid 36507043)
16. Lladser A, Sanhueza C, Kiessling R, Quest AF. Is survivin the potential Achilles' heel of cancer?. Adv Cancer Res, 2011;111:1-37.
17. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 2001;41:189-207.
18. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin NP for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vision, 2007;13:746-57. (Pubitemid 46830326)
19. Nishikawa M, Takakura Y, Hashida M. Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Delivery Rev, 2005;57(5):675-88. (Pubitemid 40332596)
20. Niu X, Zou W, Liu C, Zhang N, Fu C. Modified nanoprecipitation method to fabricate DNA-loaded PLGA NP. Drug Dev Ind Pharm, 2009; 35(11):1375-83.
21. Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B, Rödel F. Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblas-toma. Radiother Oncol, 2011;101(1):51-8.
22. Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. Human serum albumin-polyethylenimine NP for gene delivery. J Controlled Release, 2003;92(1-2):199-208. (Pubitemid 37130132)
23. Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res, 2005;65(11):4881-7. (Pubitemid 40740827)
24. Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, Rödel C. The role of survivin for radiation oncology: Moving beyond apoptosis inhibition. Curr Med Chem, 2011;18(2):191-9.
25. Steinhauser I, Langer K, Strebhardt K, Spänkuch B. Uptake of plasmid-loaded NP in breast cancer cells and effect on Plk1 expression. J Drug Target, 2009;17(8):627-37.
26. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J, Schwartz D, et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin NP. Biomaterials, 2009; 31(8):2388-98.
27. Weber C, Reiss S, Langer K. Preparation of surface modified protein NP by introduction of sulfhydryl groups. Int J Pharm, 2000;211(1-2): 67-78. (Pubitemid 32008385)
28. Yang Y, Gao Y, Chen L, Huang Y, Li Y. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adria-mycin by PDMAE/survivin shRNA complex NP. Int J Pharm, 2010;405(1-2):188-95.
29. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin NP targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Release, 2009;137(1):78-86.
30. Zhang S, Wang G, Lin X, Chatzinikolaidou M, Jennissen HP, Laub M, Uludag H. Polyethylenimine-coated albumin NP for BMP-2 delivery. Biotechnol Progr, 2008;24(4):945-56.